Latest From MediTemp Ltd.
Looking to expand beyond Adcetris, Seattle Genetics pays $250m up front for Immunomedics' Phase I/II ADC for triple-negative breast cancer. Elsewhere in the ADC space, Swiss biotech Novimmune and South Korea's LegoChem are teaming up on a research collaboration.
At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced September-October 2015.
- Medical Devices
- Therapeutic Areas
- Gynecological, Urological
- Middle East
- Parent & Subsidiaries
- MediTemp Ltd.
- Senior Management
Jacob Dagan, Pres. & CEO
Fathallah Nahhas, CTO
Boris Yudkevich, MD, Medical Dir.
- Contact Info
Phone: 4 8644410
P.O. Box 45810 Haifa, 31457
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.